Latest Andrew Witty Stories
LONDON, October 22, 2014 /PRNewswire/ -- Amid continued pricing pressure in the Respiratory business, Sir Andrew Witty, CEO, has announced a restructuring of the pharmaceutical
LONDON, July 23, 2014 /PRNewswire/ -- Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition
LONDON, March 18, 2014 /PRNewswire/ -- UK government, leading industrial, investor and academic speakers to review strategies to support the commercialisation of academic
Amid accusations of bribery and scandal, GlaxoSmithKline (GSK), one of the leading drug makers, will stop paying doctors to promote its drugs.
British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share.
Pharmaceutical giant GlaxoSmithKline pleaded guilty and has agreed to pay the largest fine in US history over charges that it marketed drugs for unauthorized uses, held back safety data, and cheated the government’s Medicaid program.
LONDON, July 26, 2011 /PRNewswire/ -- UK pharma group GlaxoSmithKline reports a 2% sales dip in the second quarter but highlights strong underlying sales momentum. In an interview with financial broadcaster http://www.cantos.com, CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall delivery of strategy, declining "headwinds", R&D strategy, improving margins and a review of the recently implemented Drug Performance Units. The interview...